The crime of the Tuskegee Syphilis Experiment isnít that it was an
experimentómedicine improves only through smart experiments. What made
Tuskegee so shameful was that a cure for syphilis had finally been
discovered, but news of the cure was deliberately kept from the
patients who needed it the most, patients with tertiary stage syphilis.
For the past 6 years, the world has been in the midst of a situation
hundreds of times worse than Tuskegee. Like the Tuskegee syphilitics,
the patients affected arenít even aware of the injustice. As in
Tuskegee, patients are paying with their lives.
In 2002, I published a method to reverse diabetic and hypertensive
kidney failure (1), which works for whites, blacks, and
Hispanics. Dialysis, the kidney machine, claims blacks at least 5
times more than whites, and Hispanics about 3 times more than whites.
The media refused to take my word for it, requiring me to get an endorsement from somebody in the renal community.
I suppose that's fair enough, but somewhat depressing: even Larry
Altman MD, the medical reporter for the New York Times, confessed to me
that he couldn't evaluate a scientific paper on its own merits. Science
majors learn how to do this their freshman year in college.
Since 2002, not a single medical authority has come forward to
endorse my study, even though the founding Director of the US Renal
Data System, Dr Lawrence Agodoa, called my data "beautiful" in a
conference call in early 2004. He said the rules of the NIH, his
employer, refused to let him endorse a company. That's the same
response the American Diabetes Association gave me, even though they
partially funded the underlying research. It's also what the National
Kidney Foundation told me. Apparently this applies even if a company
discovers a cure for the disease they're working on, which seems a bit
counter-productive, as far as the public is concerned.
Apparently, no non-profit wants to repeat the mistake of the March
of Dimes, who cured their raison d'etre, polio, in the 1950s.
In October, 2004, I presented my paper to the then Medical Director
of Medicare, Sean Tunis, and his senior staff, including Sandy Foote.
Medicare is the "single-payer" for dialysis and kidney transplantation,
and currently spends about $25 billion a year for end-stage kidney
Incredibly, they had no interest. Only then did it dawn on me
that they'd be eliminating 90% of their own jobs along with 90% of
their budget, something every bureaucrat is terrified of doing.
Neither did the NIDDK (the Kidney Institute at the NIH), the
American Heart Association, the American Association for Kidney
Patients, the CDC, the AMA, the National Medical Association (the black
AMA), numerous academic Nephrology Divisions, numerous kidney
transplantation societies, individual nephrologists and transplant
surgeons, multiple health insurance companies, multiple health plans,
all 50 state Medicaid offices, even religious leaders vocal about
healthcare, et al. (2).
Even the Missouri Kidney Program, which co-funded the key research along with the ADA, has had no comment.
The head of Anthem Blue Cross/Blue Shield, whom I know personally,
and who is now head of Wellpoint, with over 100 million patients, told
me that my 1,000 patients weren't enough. "Come back when you have
100,000," he said, knowing full well that it took me 9 years to publish
my paper on 1,000 patients. At that rate, he could safely wait 900 more
About 50,000 patients go on dialysis in the US every year. My method
could prevent 90% of whites, and 95% of African Americans, from losing
their kidney function. It's fair to say that, had my paper received the
notice it required, back in 2002, 90-95% of patients could have been
kept off the kidney machine at least since 2006, and perhaps earlier.
(I have to treat patients early, before they've lost half their kidney
function, i.e. while their serum creatinine is less than 2 mg/dl. Once
theyíre on dialysis, itís too late).
Conservatively speaking, 100,000 patients are currently on dialysis
whom I could have kept off, had anyone at the NIH, CDC, NKF, etc.
simply spoken to a reporter about my paper.
Once on dialysis, patients live only a handful of years. A 65 year
old man starting dialysis has a life expectancy of 2.5 years--as
opposed to decades with syphilis.
So I reckon the collective silence of the medical community,
including government as well as non-profit institutions, is at least
250 times worse than their silence during the Tuskegee experiment: 400
Tuskegee patients vs. 100,000 dialysis patients. And the crime
continues. Each day, another 135 patients go on dialysis for the first
time, and soon die, 125 of whom GenoMed could have prevented.
This issue painfully illustrates what's really wrong with US
healthcare, indeed, with hospital-based healthcare everywhere around
the globe. Its business model requires disease. Patients must get sick
in order for the revenues to keep flowing. A dialysis patient brings in
$100,000 annually for the roughly 3 years s/he's alive. See, for
So access is not the real issue; quality improvement
is. Spreading manure doesn't change it. Healthcare everywhere, not
just in the US, is anti-innovative and therefore exploitative.
Single-payer advocates should know that Medicare is already a
single-payer for dialysis. National Health Services in other countries,
e.g. Canada, Germany, Spain, France, Germany, Russia, Japan, Singapore,
etc. have had no interest in my method of preventing dialysis, either.
In other words, on the global scale, Medicare is not alone.
I submit that the presidential debate about healthcare is
dangerously uninformed without taking into account this stark example
of whatís really wrong with the industry. The fix is simple: build in
competition on outcomes. Start by reporting outcomes.
This is an extremely simple solution thatís practically free: just
mandate reporting of patient outcomes for anybody getting paid with
federal dollars (and that involves most patients). Post clinical
outcomes for each insurance plan, each hospital, and each physician on
the web, for all to see. How many diabetic patients seen by Dr. X go on
dialysis? How many in Dr. Yís practice?
Continue to let patients vote with their feet. This would ensure
competition on outcomes, and tie economic survival of health plans and
practitioners to their patientsí survival. In one neat trick, we will
have inverted the current business model for healthcare, so that it
actually benefits patients rather than kills them.
1. Moskowitz DW. From pharmacogenomics to improved patient outcomes:
angiotensin I-converting enzyme as an example. Diabetes Technol Ther.
2002;4(4):519-32. PMID: 12396747. (For PDF file, click on paper #1 at: http://www.genomed.com/index.cfm?action=investor&drill=publications)--this
paper reports on 1,000 white and black male veterans. An additional 350
Hispanic men and women with diabetes were treated during the period
2001-2007, and showed no progression of their normal kidney function